Ptc Therapeutics (PTCT) Income towards Parent Company (2012 - 2026)

Ptc Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 100.32% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$177.1 million, a 115.18% decrease from a year earlier, with the FY2025 full-year figure at $692.2 million, up 231.38% from the prior year.
• Income towards Parent Company improved to -$2.8 million in Q1 2026 per PTCT's latest filing, from -$125.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $866.6 million in Q1 2025 and bottomed at -$286.7 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$109.3 million (2022), against an average of -$26.7 million.
• Biggest YoY gain for Income towards Parent Company was 1046.28% in 2025; the steepest drop was 124.77% in 2025.
• Year by year, Income towards Parent Company stood at -$207.2 million in 2022, then tumbled by 38.36% to -$286.7 million in 2023, then soared by 276.59% to $506.3 million in 2024, then plunged by 124.77% to -$125.4 million in 2025, then surged by 97.76% to -$2.8 million in 2026.
• Per Business Quant, the three latest PTCT Income towards Parent Company figures stand at -$2.8 million (Q1 2026), -$125.4 million (Q4 2025), and $15.9 million (Q3 2025).